PT  - JOURNAL ARTICLE
AU  - Amanda C. Guidon
AU  - Anthony A. Amato
TI  - COVID-19 and neuromuscular disorders
AID  - 10.1212/WNL.0000000000009566
DP  - 2020 Jun 02
TA  - Neurology
PG  - 959--969
VI  - 94
IP  - 22
4099  - http://n.neurology.org/content/94/22/959.short
4100  - http://n.neurology.org/content/94/22/959.full
SO  - Neurology2020 Jun 02; 94
AB  - The coronavirus 2019 (COVID-19) pandemic has potential to disproportionately and severely affect patients with neuromuscular disorders. In a short period of time, it has already caused reorganization of neuromuscular clinical care delivery and education, which will likely have lasting effects on the field. This article reviews (1) potential neuromuscular complications of COVID-19, (2) assessment and mitigation of COVID-19-related risk for patients with preexisting neuromuscular disease, (3) guidance for management of immunosuppressive and immunomodulatory therapies, (4) practical guidance regarding neuromuscular care delivery, telemedicine, and education, and (5) effect on neuromuscular research. We outline key unanswered clinical questions and highlight the need for team-based and interspecialty collaboration. Primary goals of clinical research during this time are to develop evidence-based best practices and to minimize morbidity and mortality related to COVID-19 for patients with neuromuscular disorders.AANEM=American Academy of Neuromuscular and Electrodiagnostic Medicine; ALS=amyotrophic lateral sclerosis; CK=creatine kinase; COVID-19=coronavirus disease 2019; FcRn=neonatal Fc receptor; FDA=Food and Drug Administration; GBS=Guillain-Barré syndrome; IST=immunosuppressive therapy; MERS=Middle East respiratory syndrome; MG=myasthenia gravis; NMD=neuromuscular disorder; SARS=severe acute respiratory syndrome; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2